O
Oliver Rick
Researcher at Charité
Publications - 53
Citations - 2459
Oliver Rick is an academic researcher from Charité. The author has contributed to research in topics: Germ cell tumors & Chemotherapy. The author has an hindex of 21, co-authored 49 publications receiving 2297 citations. Previous affiliations of Oliver Rick include University of Tübingen.
Papers
More filters
Journal ArticleDOI
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
Susanne Krege,Jörg Beyer,Rainer Souchon,Peter Albers,Walter Albrecht,Ferran Algaba,Michael Bamberg,István Bodrogi,Carsten Bokemeyer,Eva Cavallin-Ståhl,Johannes Classen,C Clemm,Gabriella Cohn-Cedermark,Stéphane Culine,Gedske Daugaard,Pieter H.M. De Mulder,Maria De Santis,Maike de Wit,Ronald de Wit,H. G. Derigs,Klaus Peter Dieckmann,Annette Dieing,Jean Pierre Droz,Martin Fenner,Karim Fizazi,Aude Flechon,Sophie D. Fosså,Xavier Garcia del Muro,Thomas Gauler,Lajos Géczi,Arthur Gerl,Jose Ramon Germa-Lluch,Silke Gillessen,Jörg T. Hartmann,Michael Hartmann,Axel Heidenreich,Wolfgang Hoeltl,Alan Horwich,Robert Huddart,Michael Jewett,Johnathan Joffe,William G. Jones,László Kisbenedek,Olbjørn Klepp,S. Kliesch,Kai Uwe Koehrmann,Christian K. Kollmannsberger,Markus A. Kuczyk,Pilar Laguna,Oscar Leiva Galvis,Volker Loy,Malcolm David Mason,Graham M. Mead,Rolf Mueller,Craig R. Nichols,Nicola Nicolai,Tim Oliver,D. Ondruš,Gosse O N Oosterhof,Luis Paz Ares,Giorgio Pizzocaro,Jörg Pont,Tobias Pottek,Thomas Powles,Oliver Rick,Giovanni Rosti,Roberto Salvioni,Jutta Scheiderbauer,Hans U. Schmelz,Heinz Schmidberger,Hans-Joachim Schmoll,Mark Schrader,Felix Sedlmayer,Niels E. Skakkebæk,Aslam Sohaib,Sergei Tjulandin,Padraig Warde,Stefan Weinknecht,Lothar Weissbach,Christian Wittekind,Eva Winter,Lori Wood,Hans von der Maase +82 more
TL;DR: F refinements in the treatment of early- and advanced-stage testicular cancer have emerged from clinical trials, and expert clinical skills will continue to be one of the major determinants for the prognosis of patients with germ cell cancer.
Journal ArticleDOI
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer
Jörg Beyer,Peter Albers,Renske Altena,Jorge Aparicio,Carsten Bokemeyer,Jonas Busch,Richard Cathomas,Eva Cavallin-Ståhl,Noel W. Clarke,J. Claßen,Gabriella Cohn-Cedermark,Alv A. Dahl,Gedske Daugaard,U. De Giorgi,M. De Santis,M. de Wit,R. de Wit,Klaus-Peter Dieckmann,Martin Fenner,Karim Fizazi,Aude Flechon,Sophie D. Fosså,J. R. Germá Lluch,Jourik A. Gietema,Silke Gillessen,Aleksander Giwercman,J. T. Hartmann,Axel Heidenreich,Marcus Hentrich,Friedemann Honecker,Alan Horwich,Robert Huddart,S. Kliesch,Christian Kollmannsberger,Susanne Krege,M.P. Laguna,Leendert H. J. Looijenga,Anja Lorch,Jean-Pierre Lotz,Frank Mayer,Andrea Necchi,Nicola Nicolai,Janine Nuver,K. Oechsle,Jan Oldenburg,J. W. Oosterhuis,Thomas Powles,E. Rajpert-De Meyts,Oliver Rick,Giovanni Rosti,Roberto Salvioni,Mark Schrader,S. Schweyer,Felix Sedlmayer,Aslam Sohaib,Rainer Souchon,T. Tandstad,C. Winter,C. Wittekind +58 more
TL;DR: The main recommendations and controversies of this meeting are presented, with a particular focus on acute and late toxic effects as well as on survivorship issues.
Journal ArticleDOI
Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem Cell support for Patients with advanced metastatic Germ Cell cancer: An extended phase I/II study of the German testicular Cancer study Group
H.-J. Schmoll,Christian K. Kollmannsberger,Bernd Metzner,J. T. Hartmann,N. Schleucher,Patrick Schöffski,Jan Schleicher,Oliver Rick,Jörg Beyer,D.K. Hossfeld,Lothar Kanz,Wolfgang E. Berdel,Reinhard Andreesen,Carsten Bokemeyer +13 more
TL;DR: Repetitive cycles of high-dose VIP with peripheral stem cell support can be successfully applied in a multicenter setting and is recommended for further investigation in randomized trials.
Journal ArticleDOI
Salvage Treatment With Paclitaxel, Ifosfamide, and Cisplatin Plus High-Dose Carboplatin, Etoposide, and Thiotepa Followed by Autologous Stem-Cell Rescue in Patients With Relapsed or Refractory Germ Cell Cancer
Oliver Rick,Carsten Bokemeyer,Jörg Beyer,J. T. Hartmann,N. Schwella,D Kingreen,S. Neureither,Bernd Metzner,Jochen Casper,Hannes Wandt,Frank Hartmann,H.-J. Schmoll,G. Derigs,Arthur Gerl,Wolfgang E. Berdel,Lothar Kanz,Wolfgang Siegert +16 more
TL;DR: Treatment with TIP followed by high-dose CET is feasible and can induce long-term remissions in 25% of patients with relapsed or refractory germ cell tumors, and peripheral nervous toxicity in approximately one third of patients is a disadvantage of this salvage strategy.
Journal ArticleDOI
Combination Chemotherapy With Gemcitabine Plus Oxaliplatin in Patients With Intensively Pretreated or Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group
Christian K. Kollmannsberger,Jörg Beyer,Ruediger Liersch,P. Schoeffski,Bernd Metzner,J. T. Hartmann,Oliver Rick,K. Stengele,K. Hohloch,C Spott,Lothar Kanz,Carsten Bokemeyer +11 more
TL;DR: Gemcitabine plus oxaliplatin demonstrates antitumor activity with acceptable toxicity in heavily pretreated patients with relapsed or cisplatin-refractory germ cell cancer, and may offer a chance of long-term survival for selected patients.